ESMO 2017 Congress: Tumours with rare oncogenic lesions – From pre-clinical to clinical validation

The European Organisation for Research and Treatment of Cancer (EORTC) in partnership with the European Society for Medical Oncology (ESMO) and the European Association for Cancer Research (EACR) organizes a session addressing tumours with rare oncogenic lesions on Sunday, September 10^th 2017 from 11:00 – 12:30 in the Pamplona Auditorium of IFEMA, Madrid (Spain). This session will be chaired by Rolf Stahel who is ESMO’s Chair of the Membership Committee, Anton Berns as EACR representative and Roger Stupp as EORTC representative.

The aim of this session is to bring oncology professionals together to facilitate interaction and bridge knowledge sharing between the laboratory and clinic.

Anton Berns (Amsterdam, The Netherlands) will introduce the session. He is the Director of research and Chairman of the board of Directors of the Netherlands Cancer Institute, as well as President of the EACR.

Alberto Bardelli (Candiolo, Italy) is Professor at the department of oncology of the University of Torino and serves on the EACR Board as President Elect during the Presidency of Anton Berns. He will talk about targeting the stem of cancer, more specifically, the inhibition of the WNT pathway in colorectal tumours.

Richard Marais (Manchester, UK) is the Director of the Cancer Research UK Manchester Institute and Professor of molecular oncology at the University of Manchester. He is a world-leading expert in the causes of melanoma and will discuss the use of rare mutations to guide treatment options in drug-resistant melanoma.

Daniel Cahill (Boston, USA) is a neurosurgeon-scientist focused on the care of brain tumour patients and improving clinical trials for these patients. He will explain the vulnerabilities of gliomas with IDH1 mutations.

Laura Van ‘T Veer (San Francisco, USA) is a world-renowned molecular biologist and leader of the UCSF Helen Diller Family Comprehensive Cancer Center Breast Oncology Program. She will detail the use of biomarkers for PARP responders.

Roger Stupp (Northwestern University Chicago, USA), past EORTC President is an internationally recognized medical oncologist and a leading authority in brain tumors. He will summarize the key messages and formulate the take-home messages of  this most interesting session.

We are pleased to invite you at the ESMO Congress, one the most influential annual meeting for oncology professionals, and look forward to welcoming you to our utmost interesting session.

More information about the EORTC session on the congress website.